Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 7FL: Nivolumab in ER+/HER2- Breast Cancer
NCT04109066Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Nivolumab Arm with Placebo Arm (2 arms). Primary endpoint: Pathological Complete Response Rate at 37 months. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04109066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109066.